secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0001628280-23-027398
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics Q2 net loss $29.5M; cash $284.3M; AML combo study starting Q3 2023
--------------------------------------------------------------------------------

- Net loss of $29.5M for Q2 2023 vs $27.3M in Q2 2022.
- Cash, cash equivalents & marketable securities of $284.3M, providing runway into H2 2025.
- Collaboration revenue $5.6M (up from $4.5M YoY), primarily from Lilly agreement.
- FHD-286 combination study in AML to begin Q3 2023 after resolving clinical hold.
- Pipeline advancing: selective BRM, ARID1B, EP300, CBP programs toward IND; six new INDs targeted in 4 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023027398/0001628280-23-027398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023027398/fhtx-20230804.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-027398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer